title: Continuous glucose monitoring: an Endocrine Society Clinical Practice Guideline.
abstract: OBJECTIVE
  The aim was to formulate practice guidelines for determining settings where patients are most likely to benefit from the use of continuous glucose monitoring (CGM).
  
  
  METHODS
  The Endocrine Society appointed a Task Force of experts, a methodologist, and a medical writer.
  
  
  METHODS
  This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence.
  
  
  METHODS
  One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society, the Diabetes Technology Society, and the European Society of Endocrinology reviewed and commented on preliminary drafts of these guidelines.
  
  
  CONCLUSIONS
  The Task Force evaluated three potential uses of CGM: 1) real-time CGM in adult hospital settings; 2) real-time CGM in children and adolescent outpatients; and 3) real-time CGM in adult outpatients. The Task Force used the best available data to develop evidence-based recommendations about where CGM can be beneficial in maintaining target levels of glycemia and limiting the risk of hypoglycemia. Both strength of recommendations and quality of evidence were accounted for in the guidelines.
authors: Mills-Peninsula Health Services, San Mateo, California 94401, USA.
authors: David C
authors: DC
authors: Klonoff
authors: Bruce
authors: B
authors: Buckingham
authors: Jens S
authors: JS
authors: Christiansen
authors: Victor M
authors: VM
authors: Montori
authors: William V
authors: WV
authors: Tamborlane
authors: Robert A
authors: RA
authors: Vigersky
authors: Howard
authors: H
authors: Wolpert
mesh_terms: D000293:Adolescent; D000328:Adult; D001786:Blood Glucose / Q000032:analysis* / Q000378:metabolism; D002648:Child; D032921:Consensus; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy; D004704:Endocrinology / Q000592:standards*; D019317:Evidence-Based Medicine; D006760:Hospitalization; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use; D007332:Insulin Infusion Systems; D008991:Monitoring, Physiologic; D010045:Outpatients
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin